2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

LuminX Biotech Co., Ltd

Biomedical EcoSystem development office in Taiwan, BEST

July 24th (Fri) 19:30 - 21:00 Entrepreneur Pitch 3

LuminX Biotech Co., Ltd

Company Info

Name /LuminX Biotech Co., Ltd

Address /9F.-1, No. 213, Sec. 2, Xinyi Rd., Zhongzheng Dist., Taipei City 100, Taiwan (R.O.C.)

Website /www.luminxbiotech.com

Presenter

Name /Dr. Long-Jyun Su

Title /CEO

Email /harrysu1006@gmail.com

Telephone /

Fax /

Mobile /0972-622756

Company Type

Biotechnology

About the Company

LuminX dedicates to accelerate the optimization of cell-therapy-products through specific understanding of therapeutic cells distribution in-vivo, long-term viability, as well as their biological fate either in preclinical or clinical setting, and our technologies can transition a potential therapy from the research stage to advanced clinical and commercial applications to save lives.

Brief Description of main products or services

A Pharmacokinetic Platform for Preclinical Evaluation of Therapeutic Cells (CellCRO platform)

Reliable detection and the biodistribution of therapeutic cells within the entire body has long been needed to treat and alter the course of diseases which cannot be addressed adequately by existing pharmaceuticals.

Here we can provide:

  • A viable application of fluorescent nanodiamonds (FNDs) for background-free imaging and quantitative tracking of therapeutic cells can meet this imperative need.
  • The simplicity of this magnetically modulated fluorescence method, together with FNDs as well as the large quantity of the nanoparticles taken up by the cells, has permitted studies of the biodistribution and pharmacokinetics of FND-labeled therapeutic cells in preclinical evaluation and clinical settings, namely CellCRO platform.
  • The technique is in excellent compatibility with time-gated fluorescence imaging, which have been shown to be a powerful means in acquiring high-contrast fluorescence imaging of FND-labeled cells in tissues.
  • The ability to find single therapeutic cells is particularly valuable for ex-vivo histological detection of these cells in clinical trials.
  • This combined approach represents an appealing alternative to hazardous radioisotope labeling techniques in cell therapy applications.

Contact Person

Name /Dr. Long-Jyun Su

Email /harrysu1006@gmail.com

Phone /0972-622756